Who
Patrick J. Haley
EVP, Commercial
Company insider
Files Form 4 as: EVP, Commercial, Exelixis.
In numbers
- Trades disclosed
- 206
- Buys
- 0
- Sells
- 63
- Bought
- $0
- Sold
- $40.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 19 Dec 2016
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.6M32,110 at $49.81 | filing |
| 20 May 2026filed 22 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.6M32,110 at $49.81 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.7M33,265 at $51.10 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.7M33,265 at $51.10 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —40,459 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —40,459 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $133K3,036 at $43.84 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.8M64,778 at $43.50 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $133K3,036 at $43.84 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $2.8M64,778 at $43.50 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.4M31,483 at $43.92 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.4M31,483 at $43.92 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —139,508 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.5M32,332 at $45.23 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —139,508 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.5M32,332 at $45.23 | filing |
| 21 Nov 2025filed 24 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.2M28,043 at $42.58 | filing |
| 20 Nov 2025filed 24 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $421K10,000 at $42.11 | filing |
| 20 Nov 2025filed 24 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $987K23,539 at $41.93 | filing |
| 20 Nov 2025filed 24 Nov 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $445K10,648 at $41.77 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Patrick J. Haley; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.